News
LXRX
0.3665
+2.66%
0.0095
Weekly Report: what happened at LXRX last week (0303-0307)?
Weekly Report · 4d ago
Lexicon Pharmaceuticals Faces Supply Chain Risks Amidst Changing Trade Policies
TipRanks · 5d ago
Vistra, Ardelyx, Zscaler, Lexicon, Arista: Trending by Analysts
TipRanks · 6d ago
Lexicon Pharmaceuticals’ Mixed Earnings Call: Achievements and Challenges
TipRanks · 03/08 00:19
Lexicon Pharmaceuticals, Inc. (LXRX) Annual Report (Form 10-K) for the Fiscal Year Ended December 31, 2024
Press release · 03/07 22:30
Lexicon Pharmaceuticals GAAP EPS of -$0.09 beats by $0.02, revenue of $26.6M beats by $24.6M
Seeking Alpha · 03/07 17:07
Lexicon Pharma Is Maintained at Overweight by Piper Sandler
Dow Jones · 03/07 15:51
Lexicon Pharma Price Target Cut to $6.00/Share From $10.00 by Piper Sandler
Dow Jones · 03/07 15:51
Piper Sandler Maintains Overweight on Lexicon Pharmaceuticals, Lowers Price Target to $6
Benzinga · 03/07 15:41
What Analysts Are Saying About Lexicon Pharmaceuticals Stock
Benzinga · 03/07 13:00
Lexicon Pharma Price Target Maintained With a $4.00/Share by HC Wainwright & Co.
Dow Jones · 03/07 12:12
Lexicon price target lowered to $6 from $10 at Piper Sandler
TipRanks · 03/07 12:04
HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $4 Price Target
Benzinga · 03/07 12:02
Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE), Lexicon Pharmaceuticals (LXRX) and Xtant Medical Holdings (XTNT)
TipRanks · 03/07 11:51
Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025
Barchart · 03/07 07:30
Lexicon Pharmaceuticals Advances Pipeline Amid Financial Growth
TipRanks · 03/07 04:26
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 03/06 22:10
Lexicon Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 03/06 22:01
Lexicon reports Q4 EPS (9c), consensus (12)
TipRanks · 03/06 21:22
*Lexicon Pharma On Track for IND Filing This Yr for LX9851 in Obesity and Other Potential Metabolic Disorders >LXRX
Dow Jones · 03/06 21:04
More
Webull provides a variety of real-time LXRX stock news. You can receive the latest news about Lexicon Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About LXRX
More
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.
Recently
Symbol
Price
%Change